600721 百花医药
2025/122024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)5.2155.6621.889-5.1579.200
总资产报酬率 ROA (%)3.6793.8111.257-3.5056.114
投入资产回报率 ROIC (%)4.2734.5871.551-4.2877.646

边际利润分析
销售毛利率 (%)45.52951.18849.03739.91840.039
营业利润率 (%)11.3949.6014.862-8.78622.584
息税前利润/营业总收入 (%)11.1069.1944.229-9.25822.061
净利润/营业总收入 (%)10.47810.7533.513-9.92821.281

收益指标分析
经营活动净收益/利润总额(%)176.263251.468413.100-82.17354.055
价值变动净收益/利润总额(%)-16.5229.14211.860-0.0340.707
营业外收支净额/利润总额(%)-0.187-0.464-8.9464.282-2.197

偿债能力分析
流动比率 (X)2.2911.8871.8311.7491.844
速动比率 (X)2.1681.5641.4261.2321.079
资产负债率 (%)26.94431.93833.46433.41030.139
带息债务/全部投入资本 (%)11.34214.76712.72811.98410.955
股东权益/带息债务 (%)736.745543.623642.967687.595765.453
股东权益/负债合计 (%)271.136213.107198.825199.308230.123
利息保障倍数 (X)-41.735-25.331-18.028117.429-581.341

营运能力分析
应收账款周转天数 (天)95.34845.45517.45119.09225.494
存货周转天数 (天)110.700214.662262.317294.099408.022